<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567852</url>
  </required_header>
  <id_info>
    <org_study_id>HRRC#: 11-236</org_study_id>
    <nct_id>NCT01567852</nct_id>
  </id_info>
  <brief_title>Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time</brief_title>
  <official_title>The Use of Ketamine Versus Methohexital for Electroconvulsive Therapy: A Cross-Over Comparative Study on Patient Recovery and Re-Orientation Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When undergoing ECT treatments, patient recovery time and re-orientation time may be shorter
      using ketamine for induction than using methohexital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ECT treatments are done under general anesthesia, and the induction is commonly done with
      methohexital. We will study whether using ketamine as an induction agent will result in a
      faster recovery time and quicker re-orientation time compared to using methohexital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Re-orientation Time</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be scored based on 5 questions (name, age, year, day of week, location). Each patient will be scored prior to induction as to how many questions they score correctly. Patient is deemed re-oriented when they score the same as baseline after the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery Time</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recovery was assessed using 5 criteria (blood pressure, voluntary movement, oxygen requirement, consciousness, respiratory effort). Each criteria was scored from 0-2, with a full score of 10. The patient is scored at baseline, and is deemed recovered when all criteria has reached baseline score again.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Post-anesthesia Recovery</condition>
  <condition>Orientation</condition>
  <arm_group>
    <arm_group_label>Ketamine First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methohexital First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect</description>
    <arm_group_label>Ketamine First</arm_group_label>
    <arm_group_label>Methohexital First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methohexital</intervention_name>
    <description>Methohexital (1.5mg/kg) will be given for induction</description>
    <arm_group_label>Ketamine First</arm_group_label>
    <arm_group_label>Methohexital First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients eligible for ECT with a primary mood disorder (bipolar disorder, major
             depressive disorder) will be eligible to participate in this study. - Patients must
             have decisional capacity and must be able to consent for this study.

        Exclusion Criteria:

          -  patients with a primary psychotic disorder (schizophrenia, schizoaffective disorder);
             patients designated as having an American Society of Anesthesiologist (ASA) Status of
             greater than 3;

          -  patients with a known allergic reactions to methohexital , ketamine and
             succinylcholine;

          -  patients with current or previous history of aneurysms, intracranial bleeds, or
             intracranial hypertension;

          -  patients with uncontrolled severe hypertension.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Yen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>December 15, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2012</firstreceived_date>
  <firstreceived_results_date>May 21, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>orientation</keyword>
  <keyword>post-anesthesia recovery</keyword>
  <keyword>electroconvulsive therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Methohexital</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine Then Methohexital (Alternating Each Trial)</title>
          <description>This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine. Each induction is counted as one trial. Each trial is followed by a day of no treatment (2 days for weekends).
Ketamine: Ketamine (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect
Methohexital: Methohexital (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect</description>
        </group>
        <group group_id="P2">
          <title>Methohexital Then Ketamine (Alternating Each Trial)</title>
          <description>This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital. Each induction is one trial. Each trial is followed by one day of no treatment (2 days for weekends).
Ketamine: Ketamine (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect
Methohexital: Methohexital (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ECT discontinued</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine First</title>
          <description>This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
Ketamine: Ketamine (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect
Methohexital: Methohexital (1-1.5mg/kg) will be given for induction</description>
        </group>
        <group group_id="B2">
          <title>Methohexital First</title>
          <description>This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
Ketamine: Ketamine (1-1.5mg/kg) will be given for induction, with room to titrate up to induction effect
Methohexital: Methohexital (1-1.5mg/kg) will be given for induction</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.75" spread="13.46"/>
                <measurement group_id="B2" value="54" spread="22.63"/>
                <measurement group_id="B3" value="52.65" spread="17.17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Re-orientation Time</title>
        <description>Patients will be scored based on 5 questions (name, age, year, day of week, location). Each patient will be scored prior to induction as to how many questions they score correctly. Patient is deemed re-oriented when they score the same as baseline after the treatment.</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Since this was a crossover study, all patients received both drugs, except for 2 patients who dropped out after receiving the first drug. For one of these patients the drug was ketamine, for the other the drug was methohexital. Number of total trials analyzed was 69, with 35 Ketamine trials and 34 Methohexital trials</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Inductions</title>
            <description>Patients receiving Ketamine inductions for ECT</description>
          </group>
          <group group_id="O2">
            <title>Methohexital Inductions</title>
            <description>Patients receiving methohexital for inductions</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Re-orientation Time</title>
            <description>Patients will be scored based on 5 questions (name, age, year, day of week, location). Each patient will be scored prior to induction as to how many questions they score correctly. Patient is deemed re-oriented when they score the same as baseline after the treatment.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24.5" spread="1.6"/>
                  <measurement group_id="O2" value="19.5" spread="1.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recovery Time</title>
        <description>Recovery was assessed using 5 criteria (blood pressure, voluntary movement, oxygen requirement, consciousness, respiratory effort). Each criteria was scored from 0-2, with a full score of 10. The patient is scored at baseline, and is deemed recovered when all criteria has reached baseline score again.</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Please see description from outcome 1</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Inductions</title>
            <description>Patients receiving Ketamine inductions for ECT</description>
          </group>
          <group group_id="O2">
            <title>Methohexital Inductions</title>
            <description>Patients receiving methohexital for inductions</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Recovery Time</title>
            <description>Recovery was assessed using 5 criteria (blood pressure, voluntary movement, oxygen requirement, consciousness, respiratory effort). Each criteria was scored from 0-2, with a full score of 10. The patient is scored at baseline, and is deemed recovered when all criteria has reached baseline score again.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.6" spread="2.0"/>
                  <measurement group_id="O2" value="27.2" spread="1.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Due to the cross-over, the same participant experienced different adverse effects according to which medication they received for induction. Hence, the number of adverse events is reported per trial (each trial is one induction) instead of per participant. There was a total of 35 trials with ketamine, and 34 trials with methohexital.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketamine Inductions</title>
          <description>Number of trials receiving ketamine inductions. Each trial is one induction.</description>
        </group>
        <group group_id="E2">
          <title>Methohexital Inductions</title>
          <description>Number of trials receiving methohexital inductions. Each trial is one induction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anesthesia Awareness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tony Yen</name_or_title>
      <organization>University of NewMexico</organization>
      <phone>505-272-2610</phone>
      <email>tyen@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
